The Trump US administration has signed a $345m four-year contract with Virginia-based Phlow Corp to manufacture generic medicines and active pharmaceutical ingredients to help treat Covid-19, according to the New York Times (NYT).
The aim is to prevent shortages of essential medicines and reduce the US market’s dependence on India and China to manufacture necessary drugs; the latter is in line with Trump’s ‘America first’ policy.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The NYT reported that there have been indications that this contract could be expanded to $812m over ten years.
The US administration is set to release further details of this investment into Phlow Corp later on today.
